A North Carolina federal magistrate judge has recommended the dismissal of a lawsuit by Novan Inc. shareholders alleging omissions and misinformation artificially inflated the company's share price, saying the investors failed to present sufficient evidence of deception or deliberate withholding of information.
A former Walmart pharmacist has asked a Texas state court for more than $1 million, alleging her manager favored black pharmacists and she was fired after working more than 20 years for the retail giant because she is white.
The U.S. Supreme Court will hear arguments Tuesday on whether the America Invents Act narrowed the on-sale bar in patent cases, tackling a question that has lingered since the law was enacted more than seven years ago.
Walmart and three pharmaceutical companies were hit with a proposed class action in Florida federal court Saturday alleging they contributed to the production and sale of contaminated batches of a drug used to treat high blood pressure and diabetes.
Sanofi should not yet be allowed to leave multidistrict litigation to pursue claims elsewhere that EpiPen maker Mylan used anti-competitive practices to hurt sales of Sanofi’s competing emergency allergy treatment, Mylan told a Kansas federal court Friday.
A panel of Federal Circuit judges on Monday questioned whether they should reconsider the $248 million in damages a lower court had ordered Zimmer Inc. to pay for infringing Stryker Corp.'s surgical tool patents.
A Delaware bankruptcy judge on Monday approved second-day motions for pharmaceutical company Egalet Corp.'s Chapter 11, including the continued use of cash collateral, and signed off on the company's disclosure statement so it can solicit votes on the plan with the aim of emerging from bankruptcy in early 2019.
The U.S. Supreme Court on Monday agreed to allow the federal government to present oral arguments against reviving multidistrict litigation over Merck's alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax.
The latest in a string of trials over injuries linked to a Johnson & Johnson unit’s allegedly defective pelvic mesh products kicked off in Philadelphia as jurors heard arguments Monday that the company’s thirst for profits pushed it to sell the implants despite serious concerns about patient safety.
DLA Piper’s Eric Falkenberry quantifies litigation risk for buyers and sellers in the M&A arena, runs data boot camps for colleagues and helps dream up innovative new analytics tools, earning him a spot on our 2018 list of Data-Driven Lawyers.
GlaxoSmithKline on Monday said it will sell its Indian consumer health unit and holdings in other Asian markets to Unilever in a £3.1 billion ($3.9 billion) deal, and at the same time announced an agreement to acquire Massachusetts-based oncology biopharmaceutical firm Tesaro Inc. for $5.1 billion, with seven firms total guiding the buyers and sellers on the tie-ups.
Big Data. Statistical Analysis. Insights. Innovation. These data-driven lawyers are making their mark on the legal industry and developing systems and practices that will change the way law is practiced in the 21st century.
A long-awaited update to class action rules meant to rein in so-called professional objectors takes effect this week, and plaintiffs' firms are hopeful it will cut off a scheme by attorneys who try to profit by using objections to hold settlements hostage.
Immunotherapy lab Argos Therapeutics Inc. on Friday filed for Chapter 11 in Delaware bankruptcy court with $21 million in debt, and plans to sell its business to a buyer-in-waiting for roughly $4 million in cash and debt relief.
The Eleventh Circuit has decided that a federal district judge had been right to allow prosecutors to modify a criminal indictment against a Florida doctor who was later convicted of smuggling medical products into the U.S. as part of a health care fraud scheme.
An Indiana jury has found Medtronic PLC owes an Indianapolis spine surgeon $112 million for failing to pay him royalties on his spinal implant patents that he had assigned to the medical device company more than a decade ago, according to Medtronic's public filings.
The unsecured creditors of bankrupt Aralez Pharmaceuticals Inc. want to block a proposed $250 million asset sale to prepetition lender Deerfield Management Co. LP and an associated company, telling a New York bankruptcy court that at least $75 million of the debt Deerfield is using to bid on the assets is really just equity, and therefore worthless.
The Federal Circuit on Thursday refused to protect a subsidiary of Thermo Fisher Scientific Inc. from a discovery order in ongoing patent infringement litigation brought by medical supplier Becton Dickinson & Co., forcing the biotech company to hand over emails between its in-house counsel and employees that were shared with a third-party company.
In a stunning move, the U.S. Department of Justice on Friday told the U.S. Supreme Court that it wants to terminate a closely watched whistleblower suit against Gilead Sciences Inc., asserting that the False Claims Act case is “not in the public interest.”
Eight firms are slated to guide four initial public offerings that could raise $689 million during the week of Dec. 3, led by an estimated $500 million IPO by drug developer Moderna Inc. in what is considered the largest biotechnology IPO in history.
With few cases going to trial, many attorneys keep their oral-presentation skills sharp by teaching continuing legal education programs. To avoid giving a CLE that falls flat and damages your reputation, you must fashion a thoughtful message, control its presentation, and nail the beginning and ending, says Daniel Karon of Karon LLC.
Since the oldest members of Generation Z aren’t even finished with law school yet, law firm management is in a unique position to prepare for their entrance into the legal workforce, says Eliza Stoker of Major Lindsey & Africa.
The U.S. Supreme Court's review of Merck v. Albrecht promises to shape the way decisions of regulatory agencies — such as the U.S. Food and Drug Administration’s rejection of a drug manufacturer’s proposed label warning — can be interpreted by juries, say Alan Klein and Matthew Decker at Duane Morris LLP.
Health care featured prominently in the 2018 midterm election campaign. Here, attorneys with Debevoise & Plimpton LLP offer thoughts on what the election results and a divided Congress mean for different sectors of the health care industry.
Pharmaceutical warnings and the way they are regulated and litigated are evolving. Brand-name manufacturers face failure-to-warn suits for generic versions of their products, while generic companies may soon have to update warnings on drugs for which there are no longer brand-name versions, say Chris Essig and Schuyler Ferguson of Winston & Strawn LLP.
The new Democratic House majority is expected to direct much of its attention to executive branch oversight and accountability. Companies and their legal counsel should be prepared for a dramatically changed collateral environment as investigations cover a wide range of topics, say attorneys at WilmerHale.
In this series featuring law school luminaries, Yale Law School lecturer and Pulitzer Prize-winning reporter Linda Greenhouse discusses her coverage of the U.S. Supreme Court, the conservatives' long game and trends in journalism.
Attorneys should think beyond the Veterans Day parades and use their time and talents to help the many veterans facing urgent legal issues, says Linda Klein of Baker Donelson Bearman Caldwell & Berkowitz PC.
The modernized trade agreement between the U.S., Mexico and Canada includes provisions that should improve intellectual property transparency between the member countries and bring a certain degree of procedural uniformity, say attorneys with Snell & Wilmer LLP.
For internet publishers that have decided the risks of doing business with cannabis-related companies do not outweigh the value, the most sensible question is not whether there is some risk but how they can minimize it, say John McKay and Chris Morley of Davis Wright Tremaine LLP.